Credit Suisse »

Alnylam Pharmaceuticals Inc Note 1.000 9/1 shares owned by Credit Suisse

Quarter-by-quarter ownership of Alnylam Pharmaceuticals Inc Note 1.000 9/1 shares owned by Credit Suisse from 13F filings

Historical chart of Credit Suisse investment in Alnylam Pharmaceuticals Inc Note 1.000 9/1

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals Inc Note 1.000 9/1 held by Credit Suisse consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals Inc Note 1.000 9/1 by Credit Suisse

Quarter filed Position value Share count Share price at filing
2023-12-31 $4.5M 4.5M 1.00
2023-09-30 $7.0M 7.0M 1.00

More positions owned by Credit Suisse

Microsoft Corporation (MSFT)
Apple (AAPL)
Ubs Group SHS (UBS)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Alphabet Cap Stk Cl C (GOOG)
UnitedHealth (UNH)
Tesla Motors (TSLA)
Alcon Ord Shs (ALC)
Visa Com Cl A (V)
Meta Platforms Cl A (META)
Johnson & Johnson (JNJ)
Eli Lilly & Co. (LLY)
JPMorgan Chase & Co. (JPM)

View all positions for Credit Suisse

Top funds holding Alnylam Pharmaceuticals Inc Note 1.000 9/1

Ubs Global Asset Management Americas
Readystate Asset Management
Steelhead Partners
Calamos Advisors
Aequim Alternative Investments
Davidson Kempner Capital Management
Wolverine Asset Management
Lazard Asset Management
Zazove Associates
Shenkman Capital Management
CNH Partners
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Capstone Investment Advisors
Citadel Advisors
MacKay Shields

View all funds holding Alnylam Pharmaceuticals Inc Note 1.000 9/1